Cognito Therapeutics

Member

Cognito Therapeutics is a pioneer in non-invasive neuromodulation to treat neurodegenerative diseases and improve human cognitive performance. Cognito has received FDA Breakthrough Device Designation for the treatment of Alzheimer’s disease. The company has completed multiple clinical studies, including the Phase 2 OVERTURE study, demonstrating its investigational therapeutic has the potential to safely slow or stop cognitive decline and loss of brain volume in Alzheimer’s disease. Cognito currently is recruiting for its pivotal HOPE study. The company’s technology, used in over 40,000 patient sessions, was based on pioneering optogenetics research by scientific co-founders Professors Li-Huei Tsai and Ed Boyden at MIT. For additional information, see https://www.cognitotx.com/.